{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:08:28Z","timestamp":1783908508381,"version":"3.55.0"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The study aimed to investigate cardiotoxicity among individuals undergoing anti-human epidermal growth factor receptor 2 (HER2) therapy with a low-to-moderate risk of cardiovascular complications. Cardiac magnetic resonance (CMR) imaging was employed in the investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>HER2-positive breast cancer patients who underwent CMR examinations both before and during therapy (first follow-up: 3-5 months; second follow-up: 6-12 months) between January 2021 and December 2022 were prospectively included. Each patient was evaluated for the risk of cardiovascular toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-five HER2-positive breast cancer patients were included (48.86 \u00b1 10.34 years). Eighty-nine percent of patients had low cardiovascular toxicity risk, and 11% had moderate cardiovascular toxicity risk. At follow-up CMR, nine (25.71%) patients developed cardiac dysfunction. At follow-up 1, there was a notable decrease in left ventricular ejection fraction, stroke volume index, cardiac output index, and absolute strain values, accompanied by higher T1 and T2 values as well as end-systolic volume index compared to baseline (p \u2264  0.002). At follow-up 2, the T1 and T2 values recovered to near baseline. The cardiac output index exhibited a continuous decline (p \u2264  0.022), while other variables were similar (p &gt; 0.05). Furthermore, at follow-up 1, the T1 value displayed a marked increase in patients with 1-3 points in cardiovascular toxicity risk factors compared to those with no risk factors (p \u2264  0.043).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>It is common for patients with low-to-moderate cardiovascular risk to experience early cardiotoxicity during anti-HER2 therapy. T1 mapping was a valuable approach for quantifying the specific extent of subtle tissue damage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2025-0043","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:57:20Z","timestamp":1761551840000},"page":"510-521","source":"Crossref","is-referenced-by-count":1,"title":["Cardiotoxicity in low-to-moderate cardiovascular risk patients undergoing anti-HER2 therapy: a prospective cardiac magnetic resonance study"],"prefix":"10.2478","volume":"59","author":[{"given":"Sainan","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulei","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Fan","sequence":"additional","affiliation":[{"name":"MR Research China, GE Healthcare, Beijing Economic-Technological Development Area , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Xie","sequence":"additional","affiliation":[{"name":"MR Research China, GE Healthcare, Beijing Economic-Technological Development Area , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2026071215565096999_j_raon-2025-0043_ref_001","doi-asserted-by":"crossref","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 2020; 17: 474-502. doi: 10.1038\/s41569-020-0348-1","DOI":"10.1038\/s41569-020-0348-1"},{"key":"2026071215565096999_j_raon-2025-0043_ref_002","doi-asserted-by":"crossref","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 2022; 23: e333-e465. doi: 10.1093\/ehjci\/jeac106","DOI":"10.1093\/ehjci\/jeac106"},{"key":"2026071215565096999_j_raon-2025-0043_ref_003","doi-asserted-by":"crossref","unstructured":"Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Col Cardiol 2021; 77: 392-401. doi: 10.1016\/j.jacc.2020.11.020","DOI":"10.1016\/j.jacc.2020.11.020"},{"key":"2026071215565096999_j_raon-2025-0043_ref_004","doi-asserted-by":"crossref","unstructured":"Goulas K, Farmakis D, Constantinidou A, Kadoglou NPE. Cardioprotective agents for the primary prevention of trastuzumab-associated cardiotoxicity: a systematic review and meta-analysis. Pharmaceuticals 2023; 16: 983. doi: 10.3390\/ph16070983","DOI":"10.3390\/ph16070983"},{"key":"2026071215565096999_j_raon-2025-0043_ref_005","doi-asserted-by":"crossref","unstructured":"Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M. T1 mapping: basic techniques and clinical applications. JACC: Cardiovas Imag 2016; 9: 67-81. doi: 10.1016\/j.jcmg.2015.11.005","DOI":"10.1016\/j.jcmg.2015.11.005"},{"key":"2026071215565096999_j_raon-2025-0043_ref_006","doi-asserted-by":"crossref","unstructured":"Cheng S, Wang J, Wang Y, Qi L, Li F, Liu J, et al. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy. Eur Radiol Exper 2023; 7: 1-9. doi: 10.1186\/s41747-023-00338-9","DOI":"10.1186\/s41747-023-00338-9"},{"key":"2026071215565096999_j_raon-2025-0043_ref_007","doi-asserted-by":"crossref","unstructured":"Houbois CP, Nolan M, Somerset E, Shalmon T, Esmaeilzadeh M, Lamacie MM, et al. Serial cardiovascular magnetic resonance strain measurements to identify cardiotoxicity in breast cancer: comparison with echocardiography. JACC Cardiovasc Imaging 2021; 14: 962-74. doi: 10.1016\/j. jcmg.2020.09.039","DOI":"10.1016\/j.jcmg.2020.09.039"},{"key":"2026071215565096999_j_raon-2025-0043_ref_008","doi-asserted-by":"crossref","unstructured":"Gong IY, Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, et al. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study. Int J Cardiovasc Imaging 2019; 35: 653-62. doi: 10.1007\/s10554-018-1482-2","DOI":"10.1007\/s10554-018-1482-2"},{"key":"2026071215565096999_j_raon-2025-0043_ref_009","doi-asserted-by":"crossref","unstructured":"Song L, Brezden-Masley C, Ramanan V, Ghugre N, Barfett JJ, Chan KK, et al. Serial measurements of left ventricular systolic and diastolic function by cardiac magnetic resonance imaging in patients with early stage breast cancer on trastuzumab. Am J Cardiol 2019; 123: 1173-9. doi: 10.1016\/j. amjcard.2018.12.046","DOI":"10.1016\/j.amjcard.2018.12.046"},{"key":"2026071215565096999_j_raon-2025-0043_ref_010","doi-asserted-by":"crossref","unstructured":"Thavendiranathan P, Abdel-Qadir H, Fischer HD, Camacho X, Amir E, Austin PC, et al. Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study. J Clin Oncol 2016; 34: 2239-46. doi: 10.1200\/jco.2015.65.1505","DOI":"10.1200\/JCO.2015.65.1505"},{"key":"2026071215565096999_j_raon-2025-0043_ref_011","doi-asserted-by":"crossref","unstructured":"Bouwer NI, Liesting C, Kofflard MJM, Brugts JJ, Kock MCJ, Kitzen J, et al. 2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab. Cardiovasc Ultrasound 2021; 19: 35. doi: 10.1186\/s12947-021-00266-x","DOI":"10.1186\/s12947-021-00266-x"},{"key":"2026071215565096999_j_raon-2025-0043_ref_012","doi-asserted-by":"crossref","unstructured":"Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 2012; 18: 113-9. doi: 10.1016\/j.cardfail.2011.10.015","DOI":"10.1016\/j.cardfail.2011.10.015"},{"key":"2026071215565096999_j_raon-2025-0043_ref_013","doi-asserted-by":"crossref","unstructured":"Esmaeilzadeh M, Urzua Fresno CM, Somerset E, Shalmon T, Amir E, Fan CS, et al. A combined echocardiography approach for the diagnosis of cancer therapy-related cardiac dysfunction in women with early-stage breast cancer. JAMA Cardiol 2022; 7: 330-40. doi: 10.1001\/jamacardio.2021.5881","DOI":"10.1001\/jamacardio.2021.5881"},{"key":"2026071215565096999_j_raon-2025-0043_ref_014","doi-asserted-by":"crossref","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020; 31: 171-90. doi: 10.1016\/j.annonc2019.10.023","DOI":"10.1016\/j.annonc.2019.10.023"},{"key":"2026071215565096999_j_raon-2025-0043_ref_015","doi-asserted-by":"crossref","unstructured":"Leong DP, Cosman T, Alhussein MM, Kumar Tyagi N, Karampatos S, Barron CC, et al. Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial. Cardio Oncology 2019; 1: 1-10. doi: 10.1016\/j.jaccao.2019.06.004","DOI":"10.1016\/j.jaccao.2019.06.004"},{"key":"2026071215565096999_j_raon-2025-0043_ref_016","doi-asserted-by":"crossref","unstructured":"Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review. Cardio Oncology 2022; 4: 19-37. doi: 10.1016\/j.jaccao.2022.01.101","DOI":"10.1016\/j.jaccao.2022.01.101"},{"key":"2026071215565096999_j_raon-2025-0043_ref_017","doi-asserted-by":"crossref","unstructured":"Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging 2018; 11: 1084-93. doi: 10.1016\/j. jcmg.2018.06.005","DOI":"10.1016\/j.jcmg.2018.06.005"},{"key":"2026071215565096999_j_raon-2025-0043_ref_018","doi-asserted-by":"crossref","unstructured":"Zhao M, Chen C, Zhang C, Xu X, Tian F, Wu B, et al. Cardiotoxicity with human epidermal growth factor receptor-2 inhibitors in breast cancer: disproportionality analysis of the FDA adverse event reporting system. Int J Cardiol 2023; 375: 87-93. doi: 10.1016\/j.ijcard.2022.12.043","DOI":"10.1016\/j.ijcard.2022.12.043"},{"key":"2026071215565096999_j_raon-2025-0043_ref_019","doi-asserted-by":"crossref","unstructured":"Barbieri MA, Sorbara EE, Cicala G, Santoro V, Cutroneo PM, Franchina T, et al. Adverse drug reactions with HER2-positive breast cancer treatment: an analysis from the Italian Ph8-z.armacovigilance Database. Drugs Real World Outcomes 2021; 9: 91-107. doi: 10.1007\/s40801-021-0027","DOI":"10.1007\/s40801-021-00278-z"},{"key":"2026071215565096999_j_raon-2025-0043_ref_020","doi-asserted-by":"crossref","unstructured":"Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 2017; 19: 1-24. doi: 10.1186\/s12968-017-0389-8","DOI":"10.1186\/s12968-017-0389-8"},{"key":"2026071215565096999_j_raon-2025-0043_ref_021","doi-asserted-by":"crossref","unstructured":"Haslbauer JD, Lindner S, Valbuena-Lopez S, Zainal H, Zhou H, D\u2019Angelo T, et al. CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping. Int J Cardiol 2019; 275: 179-86. doi: 10.1016\/j.ijcard.2018.10.023","DOI":"10.1016\/j.ijcard.2018.10.023"},{"key":"2026071215565096999_j_raon-2025-0043_ref_022","doi-asserted-by":"crossref","unstructured":"Jordan JH, D\u2019Agostino RB, Jr., Hamilton CA, Vasu S, Hall ME, Kitzman DW, et al. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ Cardiovasc Imaging 2014; 7: 872-9. doi: 10.1161\/CIRCIMAGING.114.002217","DOI":"10.1161\/CIRCIMAGING.114.002217"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2025-0043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:41:51Z","timestamp":1783906911000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2025-0043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,12,1]]}},"alternative-id":["10.2478\/raon-2025-0043"],"URL":"https:\/\/doi.org\/10.2478\/raon-2025-0043","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}